Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Malignant Lymphoma

  Free Subscription


17 Blood
2 Bone Marrow Transplant
1 Haematologica
1 Hum Pathol
8 Leuk Lymphoma
1 Mod Pathol
1 N Engl J Med

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles


    ALCL: is it now a curable disease?
    Blood. 2017;130:2691-2692.
    PubMed     Text format    

  2. VILLA D
    Novel antivirals for HCV-associated lymphomas.
    Blood. 2016;128:2482-2483.
    PubMed     Text format    

  3. HUANG Q
    A striking bone marrow dyserythropoietic change but no anemia.
    Blood. 2016;128:3177.
    PubMed     Text format    

    Exposing Hodgkin-Reed-Sternberg cells.
    Blood. 2017;129:6-7.
    PubMed     Text format    

  5. XU Z, Beaulieu Bergeron M
    Near-triploid B lymphoblastic leukemia with Burkitt-like morphology.
    Blood. 2017;129:267.
    PubMed     Text format    

  6. GANZEL C, Reinus C
    Nerves in bone marrow of newly diagnosed therapy-related acute myeloid leukemia.
    Blood. 2017;129:268.
    PubMed     Text format    

    Curative radiation for orbital MZL: how much?
    Blood. 2017;129:270-271.
    PubMed     Text format    

    Recurrent mutations and targeted therapy in FL.
    Blood. 2017;129:402-403.
    PubMed     Text format    

  9. GAY C, Delarue R, Milpied N, Oberic L, et al
    Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface area.
    Blood. 2017;129:2811-2813.
    PubMed     Text format    

  10. CHIECCHIO L, Cullis JO
    De novo Richter transformation.
    Blood. 2017;129:2455.
    PubMed     Text format    

    Relapsed/refractory HL: FDG-PET is the trump card.
    Blood. 2017;130:2154-2155.
    PubMed     Text format    

  12. MISHRA A, Porcu P
    Expanding and expounding the genomic map of CTCL.
    Blood. 2017;130:1389-1390.
    PubMed     Text format    

    Brentuximab: is it time for a new "B" in ABVD?
    Blood. 2017;130:1281-1282.
    PubMed     Text format    

    High-risk DLBCL: interim PET? Not yet.
    Blood. 2017;130:1277-1278.
    PubMed     Text format    

    SOX11 holds mantle cell lymphoma's key to home.
    Blood. 2017;130:389-391.
    PubMed     Text format    

  16. EICHENAUER DA, Engert A
    R-CHOP in NLPHL: who should receive it?
    Blood. 2017;130:387-388.
    PubMed     Text format    

  17. PAGEL JM
    A Richter transformation PD-1 block party.
    Blood. 2017;129:3397-3398.
    PubMed     Text format    

    Bone Marrow Transplant

  18. ROBINSON SP, Boumendil A, Finel H, Peggs KS, et al
    Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party.
    Bone Marrow Transplant. 2018 Jan 15. pii: 10.1038/s41409-017-0067.
    PubMed     Text format     Abstract available

  19. GAUTHIER J, Poire X, Gac AC, Leclerc M, et al
    Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.
    Bone Marrow Transplant. 2018 Jan 12. pii: 10.1038/s41409-017-0018.
    PubMed     Text format     Abstract available


  20. DAVID A, Arnaud N, Fradet M, Lascaux H, et al
    c-Myc dysregulation is a co-transforming event for nuclear factor-kappaB activated B cells.
    Haematologica. 2017;102:883-894.
    PubMed     Text format     Abstract available

    Hum Pathol

  21. YABE M, Miranda RN, Medeiros LJ
    Hepatosplenic T-cell Lymphoma: A Review of Clinicopathologic Features, Pathogenesis and Prognostic Factors.
    Hum Pathol. 2018 Jan 11. pii: S0046-8177(18)30006.
    PubMed     Text format     Abstract available

    Leuk Lymphoma

  22. PHIPPS C, Lee YS, Ying H, Nagarajan C, et al
    The impact of time from diagnosis to treatment in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2018 Jan 18:1-6. doi: 10.1080/10428194.2017.1422863.
    PubMed     Text format     Abstract available

  23. BHATT S, Sarosiek KA, Lossos IS
    Interleukin 21 - its potential role in the therapy of B-cell lymphomas.
    Leuk Lymphoma. 2017;58:17-29.
    PubMed     Text format     Abstract available

  24. LADIKOU EE, Kassi E
    The emerging role of estrogen in B cell malignancies.
    Leuk Lymphoma. 2017;58:528-539.
    PubMed     Text format     Abstract available

  25. YASUHIRO T, Sawada W, Klein C, Kozaki R, et al
    Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 i
    Leuk Lymphoma. 2017;58:699-707.
    PubMed     Text format     Abstract available

  26. SONBOL MB, Hilal T, Dueck AC, Rosenthal AC, et al
    A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma.
    Leuk Lymphoma. 2018 Jan 10:1-7. doi: 10.1080/10428194.2017.1416368.
    PubMed     Text format     Abstract available

  27. COLLINS GP, Rueda A, Salles G, von Tresckow B, et al
    Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries.
    Leuk Lymphoma. 2018 Jan 16:1-8. doi: 10.1080/10428194.2017.1421762.
    PubMed     Text format     Abstract available

  28. DRACH J, Huang H, Samoilova O, Belch A, et al
    Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the random
    Leuk Lymphoma. 2018 Jan 17:1-8. doi: 10.1080/10428194.2017.1365855.
    PubMed     Text format     Abstract available

  29. KOJIMA M, Carreras J, Kikuti YY, Miyaoka M, et al
    A case of diffuse large B-cell lymphoma with MYC gene cluster amplification related to chromothripsis.
    Leuk Lymphoma. 2018 Jan 18:1-5. doi: 10.1080/10428194.2017.1421753.
    PubMed     Text format    

    Mod Pathol

  30. RYMKIEWICZ G, Grygalewicz B, Chechlinska M, Blachnio K, et al
    A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration.
    Mod Pathol. 2018 Jan 12. pii: modpathol2017186. doi: 10.1038/modpathol.2017.
    PubMed     Text format     Abstract available

    N Engl J Med

  31. SCHUSTER SJ, Svoboda J, Chong EA, Nasta SD, et al
    Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
    N Engl J Med. 2017;377:2545-2554.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.